

VRL/SEC/EXCHANGE

01.11.2023

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai Script Code: 526953
--	--

Sub.: Press Release- Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model.

Dear Sir/ Madam,

Kindly find enclosed herewith is a press release being issued by the Company on the captioned subject.

Kindly take the above information on your record.

Thank you.

Yours faithfully,
for **VENUS REMEDIES LIMITED**



Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.vmrindia.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany





PRESS RELEASE

Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model

- **Venus wins the FICCI Healthcare Award 2023 in the esteemed "Excellence in Patient Safety and Care" category**
- **Venus's pioneering 'Organ-on-a-Chip' research model has set new standards for patient safety, care, and innovative healthcare solutions**


Chandigarh, November 01, 2023: Venus, a prominent healthcare and research industry leader, is delighted to announce its exceptional achievement of winning the FICCI Healthcare Award 2023 in the esteemed "Excellence in Patient Safety and Care" category. The award recognizes Venus's groundbreaking 'Organ-on-a-Chip' research model, a first-of-its-kind development in India, showcased at the Venus Medicine Research Centre (VMRC), the organization's R&D wing.

The Federation of Indian Chambers of Commerce and Industry (FICCI) Healthcare Awards are among the most respected accolades in the healthcare sector, highlighting and honouring the outstanding contributions made by organizations and individuals towards advancing healthcare in India.

The path to this laudable achievement for Venus was marked by an intensive evaluation process, an exemplar of the rigorous standards upheld by FICCI to identify and honour meritorious contributions in patient care and safety. Venus' candidacy was scrutinized through a comprehensive written submission, followed by a detailed deliberation with the award's adjudicators, reflecting the thoroughness of the assessment and the prestige of the recognition.

The VMRC's 'Organ-on-a-Chip' model is a paradigm shift in patient safety and healthcare innovation. It is a critical enabler in the domain of medical research and pharmaceutical development, fostering advancements in personalized medicine. This state-of-the-art technology replicates human organ functionality, granting researchers unprecedented precision in their studies. It elevates the fidelity of drug efficacy tests and offers a truer reflection of a medication's interaction with human tissue, thereby enhancing drug safety profiles prior to clinical trial phases and subsequent patient availability. This model is poised to revolutionize drug development by reducing animal testing reliance, accelerating the drug approval pipeline, and tailoring patient-specific therapeutic strategies.

Speaking about this remarkable achievement, Mr Saransh Chaudhary, the CEO of Venus Medicine Research Centre, expressed his gratitude and excitement, stating, "The FICCI Healthcare Award 2023 for 'Patient Safety and Care' significantly reinforces our relentless pursuit of healthcare and pharmaceutical research excellence in India. Our 'Organ-on-a-Chip' technology is a testament to our commitment to patient safety and the elevation of healthcare standards. This commendation is a testament to our unwavering dedication."



The FICCI Healthcare Awards 2023 have brought to the forefront the extraordinary contributions made by Venus in the healthcare sector. This recognition underscores the company's commitment to innovative research, patient well-being, and the advancement of medical science in India.

Venus extends its heartfelt appreciation to the FICCI Healthcare Awards for this prestigious honour and looks forward to continuing its groundbreaking research for the betterment of healthcare in the country and beyond.

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10-leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European-GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world's 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

X--X--X

